GlassScriptPhysician profile
Ligaya V Centeno
NPI 1467479147
$25,210.28
in general payments reported to CMS, 2019-2025
47 companies · $6,244 in 2025
The $6,244 reported for 2025 was more than what 85% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,588 · 2020: $1,528 · 2021: $3,630 · 2022: $3,310 · 2023: $3,928 · 2024: $4,982 · 2025: $6,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,824.39 |
| Education | $329.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,219.69 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $3,579.04 | 2019-2025 | |
| Glaxosmithkline, LLC. | $3,563.57 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $2,284.26 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $1,345.61 | 2019-2025 | |
| Pfizer INC. | $1,292.74 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,269.24 | 2019-2025 | Dupixent |
| Incyte Corporation | $912.03 | 2021-2025 | Opzelura, Opzelura |
| Csl Behring | $721.71 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Optinose US, INC. | $694.48 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $681.80 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Amgen INC. | $522.09 | 2020-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $414.78 | 2019-2024 | Spiriva Respimat |
| Ars Pharmaceuticals Operations, INC. | $375.67 | 2025 | Neffy |
| Abbvie INC. | $359.99 | 2022-2025 | Rinvoq |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $349.34 | 2021-2025 | Orladeyo |
| Organon LLC | $325.85 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $318.96 | 2022-2025 | |
| Galderma Laboratories, L.P. | $193.32 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $193.30 | 2024-2025 | Ebglyss |
| Grifols USA, LLC | $187.08 | 2022-2025 | Xembify |
| Covis Pharma Gmbh | $166.53 | 2021-2022 | |
| Kaleo, INC. | $151.17 | 2019-2024 | Auvi-Q |
| Alk-Abello, INC | $134.43 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Encore Dermatology INC. | $99.00 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $90.42 | 2019-2021 | |
| Phadia US INC. | $77.60 | 2020-2024 | Immunocap |
| Ionis Pharmaceuticals, INC. | $71.82 | 2025 | Dawnzera |
| Leo Pharma INC. | $59.38 | 2022-2025 | Anzupgo |
| Aimmune Therapeutics, INC. | $57.52 | 2021-2022 | |
| Pharming Healthcare, INC. | $50.12 | 2019-2023 | Ruconest |
| Shire North American Group INC | $43.92 | 2019 | |
| Hikma Pharmaceuticals USA | $43.32 | 2023-2025 | Ryaltris |
| Cycle Pharmaceuticals INC | $41.91 | 2024-2025 | Sajazir |
| Blueprint Medicines Corporation | $38.57 | 2023-2024 | Ayvakit |
| Mylan Specialty L.P. | $34.94 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $34.32 | 2023 | |
| Insmed, INC. | $30.53 | 2024-2025 | Arikayce |
| Greer Laboratories, INC. | $30.07 | 2019-2024 | Palforzia |
| Pulmonx Corporation | $29.25 | 2025 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Horizon Therapeutics Plc | $25.65 | 2019-2022 | |
| Biocryst Pharmaceuticals, INC. | $23.77 | 2020 | |
| Paratek Pharmaceuticals, INC. | $17.98 | 2025 | Xhance |
| Uswm, LLC | $16.00 | 2021 | |
| Aytu Biopharma, INC. | $14.13 | 2023 | Karbinal |
| Circassia INC. | $11.85 | 2019 | |
| Bio Products Laboratory USA, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ligaya Centeno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.